ORGANOCATALYSIS · Versatile and environmentally friendly new reaction methodology for synthetic organic chemistry with application to medicinal chemistry
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2004-10-25 → 2006-06-24
- EU contribution
- €150,747
- Participants
- 2
- Scheme
- OIF
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - ORGANOCATALYSIS (Versatile and Environmentally Friendly New Reaction Methodology for Synthetic Organic Chemistry with Application to Medicinal Chemistry)
For the outgoing phase of the research project, the research objective was to develop a new enantioselective organocatalytic reductive amination for the preparation of chiral amines. The project was elaborated from initial concept through successful completion via design of a new chiral Bronsted acid catalyst to facilitate the process on a range of substrates. The results were communicated in a leading international journal and the article became the second most cited paper of 2006 in that journal. The new catalyst was recognised by commercial suppliers and would be available for purchase shortly after the project completion. For the incoming phase research project objectives were, as part of a project team within the respiratory and inflammation therapeutic area, to develop an aggrecanase inhibitor as a treatment for osteoarthritis. In general, the inhibitors of aggrecanase that were developed contained a zinc-binding group such as a reverse hydroxamate group. These zinc-binding motifs proved to be essential to gain activity. In addition to the zinc-binding group there were two other key portions of the molecule, referred to as P1 and P1' groups. They were named directly in accordance with the enzyme pocket into which they bound, known as the S1 and S1' pockets respectively. Modification of these groups permitted the ability to tune reactivity, selectivity and physical properties of the molecules. A range of molecules of this generic type were systematically designed, synthesised and tested as inhibitors against a range of a-disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) and Matrix metalloproteinases (MMP) enzymes. Molecules with a diverse range of both P1 and P1' groups were synthesised using similar chemistry. Overall, this facilitated the development of molecules that efficiently targeted the desired enzyme and simultaneously possessed useful enzyme selectivity, physical properties and pharmacokinetics. The crystal structure of a related enzyme was known and provided vital information and approximations as an aid to rational compound design. In summary, breakthroughs towards progressing key target molecules to the next stage of development were achieved as part of an established multidisciplinary project.
Data: CORDIS, © European Union
Project objective
Enantioselective catalysis is the most important frontier of synthetic organic chemistry and is essential to biomedical research and drug discovery. As nature uses enzymes to catalyze highly stereoselective reactions, it was long assumed that complex struc tures are essential to attain high enantioselectivity. However, it has now been illustrated that small molecule organic catalysts can approach the enantioselectivity and reactivity characteristics of enzymes, omitting the need for toxic organometallic cata lysts or ¿strong¿ Lewis acids. To date, surprisingly few asymmetric organocatalytic transformations have been developed, despite the availability of enantiopure organic chemicals and the accordant academic, industrial, environmental and economic benefits o ver existing methods.The proposed outgoing phase project would further the development of new enantioselective organocatalysis methods, within the pioneering research group of Prof. David MacMillan at Caltech. This research group recently designed a range of highly efficient new organocatalysts and pioneered a variety of catalytic asymmetric transformations of immense practicality and synthetic utility.The return phase would permit the development of a drug discovery project within the laboratories of Astr aZeneca. This work would complement the researcher¿s training and enable integration of the organocatalysis technologies within European industry.The mobility, importance of the research topic and high profile academia-industry collaboration would encourag e co-operation between research disciplines and provide opportunity to widely advertise participation in Marie Curie actions. Overall, the two phases would benefit a motivated European scientist to develop many new skills. Important networks of internation al communication would be established, providing a platform to assist research innovation and economic strengthening within Europe.
Original text from CORDIS.
Participants
- ASTRAZENECA UK LIMITED · LONDONCoordinatorUnited Kingdom
- CALIFORNIA INSTITUTE OF TECHNOLOGY · PASADENACity levelUnited States
Links
Data: CORDIS, © European Union
